Swiss clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer
NUCLIDIUM has raised €113M across 2 funding rounds from 13 investors, most recently a Series B round in May 2026. Based in Zurich, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2026-05-29 | Series B | €29M | Angelini Ventures,Aurea,Bayern Kapital,Existing investors,Kurma Growth Opportunities Fund,Neva SGR+3 more | View deal → |
| 2025-07-11 | Series B | €84M | Angelini Ventures,Bayern Kapital,DeepTech & Climate Fonds (DTCF),Eurazeo,Existing investors,HighLight Capital+5 more | View deal → |
